Genprex (GNPX) stock
GNPX · Genprex Inc. · NASDAQ
- Market cap
- $2.2M
- Shares out
- 1.3M
Why is GNPX stock moving today?
Data Presented at the 2026 EORTC-NCI-AACR Symposium Show TROP2 Levels May Help Predict Which Tumors Respond to Reqorsa® and Modulating TROP2 May Enhance EfficacyAUSTIN, Texas, Nov. 19, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage biotechnology company developing gene therapies designed to restore tumor-suppressor function in cancer and insulin-producing function in diabetes, today announced new preclinical data identifying low TROP2 expression as a potential predictive biomarker of primary resistance to its lead drug candidate, Reqorsa® (quaratusugene ozeplasmid), a gene therapy product, in non-small cell lung cancer (NSCLC). The findings w
All GNPX newsAre insiders buying or selling GNPX?
No GNPX insider has reported a purchase or sale in the last 90 days. The last trade on file: Brent M Longnecker sold $22, reported on Apr 15, 2026.
GNPX insider tradesFinancial highlights
Full financials- Net income, TTM
- -$16.94M
- Cash
- $15.35M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
Latest news
25 items- PRGenprex Presents Preclinical Data Identifying TROP2 as a Potential Predictive Biomarker for Reqorsa® Gene Therapy in Lung CancerData Presented at the 2026 EORTC-NCI-AACR Symposium Show TROP2 Levels May Help Predict Which Tumors Respond to Reqorsa® and Modulating TROP2 May Enhance EfficacyAUSTIN, Texas, Nov. 19, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage biotechnology company developing gene therapies designed to restore tumor-suppressor function in cancer and insulin-producing function in diabetes, today announced new preclinical data identifying low TROP2 expression as a potential predictive biomarker of primary resistance to its lead drug candidate, Reqorsa® (quaratusugene ozeplasmid), a gene therapy product, in non-small cell lung cancer (NSCLC). The findings w
- SECSEC Form 10-Q filed by Genprex Inc.10-Q - Genprex, Inc. (0001595248) (Filer)
- PRGenprex to Highlight Dual Delivery Strategy for Diabetes Gene Therapy at Future of Cell and Gene Therapy SymposiumGenprex Senior Director of Quality Control & Product Development to Present Insights from Parallel AAV and Lipid-Based Development ProgramsPresentation to Highlight Drug Development, Manufacturing and Optimization Considerations for Diabetes Gene TherapyAUSTIN, Texas, Nov. 11, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage biotechnology company developing gene therapies designed to restore tumor-suppressor function in cancer and insulin-producing function in diabetes, today announced that Pier-Anne Lachance, Ph.D., the Company's Senior Director of Quality Control & Product Development, will present at Drug Discovery News' Future of Cell and G
- SECGenprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Genprex, Inc. (0001595248) (Filer)
- PRGenprex Presents Data Showing Reqorsa® Gene Therapy Activates Cellular Repair and Maintenance Programs Linked to Aging Biology in Patients, Supporting TUSC2 as a Key Regulator of Resilience to Aging-Associated StressWhole-Blood Translational Analysis from Clinical Trial Patients Link TUSC2 to Mitochondrial Adaptation, Autophagy, and Protein Quality ControlExpands Upon Existing REQORSA Research, Supporting Potential Beyond OncologyAUSTIN, Texas, Nov. 5, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage biotechnology company developing gene therapies designed to restore tumor-suppressor function in cancer and insulin-producing function in diabetes, today announced results from a translational analysis of patients treated with its lead drug candidate, Reqorsa® (quaratusugene ozeplasmid), a gene therapy product. The data suggest that increased TUSC2 expression,
- SECGenprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Genprex, Inc. (0001595248) (Filer)
- PRGenprex Announces New Research Identifying TROP2 as a Potential Predictive Biomarker to Reqorsa® Gene Therapy in Lung CancerResearch to be Presented at the 2026 EORTC-NCI-AACR Symposium Links TROP2 Expression to Treatment Response and Explores its Role in Treatment SensitivityFindings Suggest Low TROP2 Expression is Associated with Primary Resistance to REQORSA and May Help Guide Patient SelectionAUSTIN, Texas, Nov. 4, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage biotechnology company developing gene therapies designed to restore tumor-suppressor function in cancer and insulin-producing function in diabetes, today announced new research identifying TROP2 expression as a potential predictive biomarker of response to its lead drug candidate, Reqorsa® (quaratusugen
- SECSEC Form 8-K filed by Genprex Inc.8-K - Genprex, Inc. (0001595248) (Filer)
- PRGenprex to Present TUSC2 Research from Sponsored Collaboration with Meharry Medical College at the Gerontological Society of America 2026 Annual Scientific MeetingResearch explores the role of TUSC2, the therapeutic gene used in Reqorsa® Gene Therapy in mitochondrial biology and cellular aging, supporting investigation of potential applications beyond oncologyAUSTIN, Texas, Oct. 28, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage biotechnology company developing gene therapies designed to restore tumor-suppressor function in cancer and insulin-producing function in diabetes, today announced that research conducted under its sponsored research collaboration with Meharry Medical College in Nashville, Tennessee will be featured at the Gerontological Society of America (GSA) 2026 Annual Scientific Meeting,
- SECSEC Form 8-K filed by Genprex Inc.8-K - Genprex, Inc. (0001595248) (Filer)
- PRGenprex Highlights New Preclinical Data Identifying Role of TUSC2, the Gene Used in REQORSA®, in Maintaining Cellular Function During Brain AgingCollaborators publish new peer-reviewed study identifying sex-specific effects of TUSC2 loss on mitochondrial function, protein homeostasis, and synaptic pathways, alongside molecular similarities with human brainFindings suggest that TUSC2 may play a foundational role in brain healthAUSTIN, Texas, Oct. 21, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage biotechnology company developing gene therapies designed to restore tumor-suppressor function in cancer and insulin-producing function in diabetes, today highlighted new peer-reviewed research in mice identifying an important role for the TUSC2 tumor suppressor gene in maintaining cellular pro
- PRGenprex to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceCompany Presentation to Highlight Lead Clinical Oncology Program and Preclinical Diabetes ProgramAUSTIN, Texas, Sept. 8, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), today announced that members of its executive leadership team will present at and participate in the H.C. Wainwright 28th Annual Global Investment Conference, being held September 14–16 in New York City. Genprex is a clinical-stage biotechnology company developing gene therapies designed to restore tumor-suppressor function in cancer and insulin-producing function in diabetes. The Company's lead oncology program is in clinical development, and its diabetes program is advancing through preclinica
- SECGenprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Genprex, Inc. (0001595248) (Filer)
- PRGenprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene TherapyCollaboration Allows Genprex to Accelerate Manufacturing Processes for IND-Enabling Preclinical Studies and Future Clinical TrialsAUSTIN, Texas, Aug. 18, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has entered into a development and manufacturing agreement with a leading U.S. based clinical and commercial Contract Development and Manufacturing Organization (CDMO) to initiate the manufacturing scale-up of its diabetes gene therapy program. This strategic selection allows for the transition of the Company's therape
- SECSEC Form 10-Q filed by Genprex Inc.10-Q - Genprex, Inc. (0001595248) (Filer)
- SECGenprex Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits8-K - Genprex, Inc. (0001595248) (Filer)
- SECGenprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Genprex, Inc. (0001595248) (Filer)
- PRGenprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation StudiesCollaboration Advances Biomarker-Driven Patient Selection and Precision Medicine in OncologyValidation Studies Aim to Optimize Clinical Trial Patient Selection CriteriaAUSTIN, Texas, Aug. 3, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced its collaboration with Roche Diagnostics to validate biomarkers for patient selection in clinical trials for non-small cell lung cancer (NSCLC). Building on promising preclinical and clinical data, this collaboration intends to refine patient identification using TROP2 as a biomarker.
- SECGenprex Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits8-K - Genprex, Inc. (0001595248) (Filer)
- SECGenprex Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Genprex, Inc. (0001595248) (Filer)
- SECSEC Form S-8 filed by Genprex Inc.S-8 - Genprex, Inc. (0001595248) (Filer)
- SECGenprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Genprex, Inc. (0001595248) (Filer)
- PRGenprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa® Gene Therapy with Either PD-1 or PD-L1 Antibodies to Treat CancerPatent Covers Acclaim-3 Clinical Trials Combining REQORSA Gene Therapy with Genentech, Inc.'s Tecentriq®AUSTIN, Texas, June 22, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that The Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance to Genprex for a patent covering the use of Reqorsa® Gene Therapy (quaratusugene ozeplasmid) in combination with either PD-1 or PD-L1 antibodies for the treatment of both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
- SECGenprex Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Genprex, Inc. (0001595248) (Filer)
- PRGenprex to Participate at BIO International Convention 2026The BIO International Convention Brings Together More Than 20,000 Biotech Industry Leaders From Around The WorldAUSTIN, Texas, June 17, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its team will be attending and participating at the BIO 2026 International Convention taking place June 22-25, 2026 in San Diego, California. In attendance from Genprex's executive leadership team will be Thomas Gallagher, Senior Vice President of Intellectual Property and Li
GNPX rankings
- Other7(58%)
- SEC Filings5(42%)
Genprex Inc. (GNPX) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 11 wire items for GNPX, including 6 press releases and news items and 5 SEC filings. The most recent was published Nov 19, 2026.
GNPX FAQ
8 questionsWhat does Genprex Inc. do?
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes who currently have limited treatment options. The company works with institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Its lead product candidate is REQORSA (GPX-001), which is in preclinical stage for the treatment of non-small cell...Is GNPX profitable?
No. Genprex Inc. reported a net loss of $16.94M for the twelve months ended Sep 30, 2026.How much cash and debt does GNPX have?
Genprex Inc. reported $15.35M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does GNPX stock trade?
Genprex Inc. (GNPX) is listed on NASDAQ.What sector and industry is GNPX in?
Genprex Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Genprex Inc. go public?
Genprex Inc. (GNPX) completed its IPO in 2018.What companies are similar to GNPX?
Notable peers in the same industry include MGTX (MeiraGTx Holdings plc), NTLA (Intellia Therapeutics Inc.), RCKT (Rocket Pharmaceuticals Inc.), SRPT (Sarepta Therapeutics Inc.), SLDB (Solid Biosciences Inc.). Compare GNPX side-by-side with any of them on Quantisnow.How can I track GNPX on Quantisnow?
Quantisnow aggregates Genprex Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GNPX to receive live email and push alerts on every new disclosure.
Is something on this page wrong, or out of date? Request a change